Related references
Note: Only part of the references are listed.Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
Xing Yi Woo et al.
NATURE GENETICS (2021)
Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Ye Yao et al.
CELL STEM CELL (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Yingmiao Liu et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype
Barbara Lupo et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer
Ana Barat et al.
SCIENTIFIC REPORTS (2020)
Organoids in immunological research
Yotam E. Bar-Ephraim et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials
Shailesh Advani et al.
JOURNAL OF SURGICAL ONCOLOGY (2019)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
Spatiotemporal regulation of clonogenicity in colorectal cancer xenografts
Maartje van der Heijden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
A. Capasso et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids
Ana C. F. Bolhaqueiro et al.
NATURE GENETICS (2019)
Colorectal tumor-on-a-chip system: A 3D tool for precision onco-nanomedicine
M. R. Carvalho et al.
SCIENCE ADVANCES (2019)
Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis
Rene Jackstadt et al.
CANCER CELL (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A systems mechanism for KRAS mutant allele-specific responses to targeted therapy
Thomas McFall et al.
SCIENCE SIGNALING (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
A rectal cancer organoid platform to study individual responses to chemoradiation
Karuna Ganesh et al.
NATURE MEDICINE (2019)
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Dana Rabara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
Salo N. Ooft et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
New therapies and insights into the changing landscape of colorectal cancer
Scott Kopetz
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumabas First-line Chemotherapy in Metastatic Colorectal Cancer
Aparna R. Parikh et al.
CLINICAL CANCER RESEARCH (2019)
Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga
Irene Catalano et al.
TRENDS IN CANCER (2019)
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib
Mitsukuni Suenaga et al.
CLINICAL COLORECTAL CANCER (2018)
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial
Sabine Tejpar et al.
EUROPEAN JOURNAL OF CANCER (2018)
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab
Erik van Dijk et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
Rui-Hua Xu et al.
LANCET ONCOLOGY (2018)
A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells
Hisatsugu Maekawa et al.
MOLECULAR CANCER THERAPEUTICS (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation
Jatin Roper et al.
NATURE PROTOCOLS (2018)
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Georgios Vlachogiannis et al.
SCIENCE (2018)
A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer
Tomoko Saito et al.
NATURE COMMUNICATIONS (2018)
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
Joseph M. Gozgit et al.
Oncotarget (2018)
Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids
Krijn K. Dijkstra et al.
CELL (2018)
Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology
Nobuo Sasaki et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
Intra-tumour diversification in colorectal cancer at the single-cell level
Sophie F. Roerink et al.
NATURE (2018)
Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer
Kristiaan J. Lenos et al.
NATURE CELL BIOLOGY (2018)
Organoid Modeling of the Tumor Immune Microenvironment
James T. Neal et al.
CELL (2018)
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M. Henricks et al.
LANCET ONCOLOGY (2018)
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Dominiek Smeets et al.
NATURE COMMUNICATIONS (2018)
Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer
Eri Sakai et al.
CANCER RESEARCH (2018)
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Cornelis J. A. Punt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Oncogenic Kras drives invasion and maintains metastases in colorectal cancer
Adam T. Boutin et al.
GENES & DEVELOPMENT (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer
Felipe de Sousa e Melo et al.
NATURE (2017)
Visualization and targeting of LGR5+ human colon cancer stem cells
Mariko Shimokawa et al.
NATURE (2017)
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Giovanni Germano et al.
NATURE (2017)
In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis
Jatin Roper et al.
NATURE BIOTECHNOLOGY (2017)
Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer
Kevin P. O'Rourke et al.
NATURE BIOTECHNOLOGY (2017)
Patient-derived xenografts undergo mouse-specific tumor evolution
Uri Ben-David et al.
NATURE GENETICS (2017)
Genetic dissection of colorectal cancer progression by orthotopic transplantation of engineered cancer organoids
Arianna Fumagalli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification
Philip D. Dunne et al.
NATURE COMMUNICATIONS (2017)
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
Moritz Schuette et al.
NATURE COMMUNICATIONS (2017)
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer
Claudio Isella et al.
NATURE COMMUNICATIONS (2017)
Multicolor lineage tracing reveals clonal architecture and dynamics in colon cancer
Sebastian Lamprecht et al.
NATURE COMMUNICATIONS (2017)
Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer
Min Zou et al.
CANCER DISCOVERY (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
G. Siravegna et al.
ANNALS OF ONCOLOGY (2017)
Biological and predictive role of ERCC1 polymorphisms in cancer
V. Formica et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Annette T. Byrne et al.
NATURE REVIEWS CANCER (2017)
A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer
M. A. West et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Rodrigo Dienstmann et al.
NATURE REVIEWS CANCER (2017)
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis
Masayuki Fujii et al.
CELL STEM CELL (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
A framework for understanding and targeting residual disease in oncogene-driven solid cancers
Trever G. Bivona et al.
NATURE MEDICINE (2016)
Mouse models in oncoimmunology
Laurence Zitvogel et al.
NATURE REVIEWS CANCER (2016)
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
A. J. Weickhardt et al.
BRITISH JOURNAL OF CANCER (2015)
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice
Miguel F. Sanmamed et al.
CANCER RESEARCH (2015)
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
Marc van de Wetering et al.
CELL (2015)
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Simonetta M. Leto et al.
CLINICAL CANCER RESEARCH (2015)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks et al.
LANCET ONCOLOGY (2015)
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2015)
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti et al.
NATURE (2015)
Sequential cancer mutations in cultured human intestinal stem cells
Jarno Drost et al.
NATURE (2015)
Stromal contribution to the colorectal cancer transcriptome
Claudio Isella et al.
NATURE GENETICS (2015)
A Big Bang model of human colorectal tumor growth
Andrea Sottoriva et al.
NATURE GENETICS (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids
Mami Matano et al.
NATURE MEDICINE (2015)
Mouse hospital and co-clinical trial project-from bench to bedside
John G. Clohessy et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases
Fleur Weeber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Eugenia R. Zanella et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Shyam M. Kavuri et al.
CANCER DISCOVERY (2015)
A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer
Long Bai et al.
SCIENTIFIC REPORTS (2015)
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Peter Eirew et al.
NATURE (2015)
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Sanne de Haas et al.
ANGIOGENESIS (2014)
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
D. J. Jonker et al.
BRITISH JOURNAL OF CANCER (2014)
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
Lei Cheng et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors
Yong Beom Cho et al.
JOURNAL OF SURGICAL RESEARCH (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells
Teun Guichelaar et al.
CLINICAL CANCER RESEARCH (2013)
Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
Antonija Kreso et al.
SCIENCE (2013)
Growing Self-Organizing Mini-Guts from a Single Intestinal Stem Cell: Mechanism and Applications
Toshiro Sato et al.
SCIENCE (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab
David O. Bates et al.
CLINICAL CANCER RESEARCH (2012)
Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer
Sylvia Julien et al.
CLINICAL CANCER RESEARCH (2012)
Influence of KRAS p.G13D Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab
Pablo Gajate et al.
CLINICAL COLORECTAL CANCER (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
Sabine Tejpar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts et al.
LANCET ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Intra-tumour heterogeneity: a looking glass for cancer?
Andriy Marusyk et al.
NATURE REVIEWS CANCER (2012)
Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Maarten J. Deenen et al.
CLINICAL CANCER RESEARCH (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Adrian M. Jubb et al.
LANCET ONCOLOGY (2010)
Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex
M. A. King et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study
Miriam Koopman et al.
EUROPEAN JOURNAL OF CANCER (2009)
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Toshiro Sato et al.
NATURE (2009)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy
R. Soong et al.
ANNALS OF ONCOLOGY (2008)
Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
Michael S. Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo
Owen J. Sansom et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
J Viguier et al.
CLINICAL CANCER RESEARCH (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Thymidylate synthase expression in colorectal cancer:: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy
D Edler et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
Y Shirota et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Share Paper
